ClinicaliQ Trial Snapshot
- Vaginal Fluid Derived Biomarkers in the Early Detection and Evolution of Gynaecological Cancers — Recruiting • Oncology • NCT07622953.
- What is being tested: Vaginal fluid biomarkers are being investigated as potential early detection tools for gynaecological cancers by comparing specific molecular markers in secretions between patients with confirmed cancer and cancer-free controls, tracking how these markers change during cancer development.
- Patient eligibility overview: The study includes patients undergoing investigation for suspected gynaecological cancer alongside control participants without cancer, enabling direct comparison of biomarker profiles across different disease states.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will investigate vaginal secretions in those patients with cancer versus those who are cancer free and compare changes in specific markers that change when a cancer first develops. Patients who are being investigated for any gynaecological cancer, undergoing surgery to reduce their risk of gynaecological cancer and those with confirmed gynaecological cancer undergoing anti-cancer treatment will be approached to take part in this study. Participants will be asked to provide an extra blood test, urine sample and high vaginal swab in addition to surplus primary tissue and ascitic…
Eligibility Snapshot
- : * Suspected cohort: Individuals undergoing investigations for suspected gynaecological cancer. This includes patients undergoing surgery to reduce their risk of the development of gynaecological cancers in the future * Confirmed treatment cohort: Individuals with a confirmed gynaecological cancer diagnosis undergoing anti-cancer treatment including surgical resection, chemotherapy or radiotherapy as part of their routine clinical care * Confirmed palliative cohort: Individuals with a confirmed gynaecological cancer diagnosis undergoing palliative procedures including ascitic drainage as part of their routine clinical care
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.